• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic wins Health Canada nod for SureTune3 DBS software

Medtronic wins Health Canada nod for SureTune3 DBS software

June 6, 2017 By Fink Densford

Medtronic logo

Medtronic (NYSE:MDT) said today it won Health Canada approval for its SureTune3 software designed for programming deep brain stimulation therapy.

The Fridley, Minn.-based company said the DBS Therapy system is licensed by Health Canada for treating diseases such as Parkinsons and for treating symptoms such as tremors through the application of mild electrical stimulation to precise targets in the brain.

The SureTune3 provides patient-specific visualization of lead location and simulated volume of neural activation to aid physicians in decision making during the programming of DBS therapy treatments. Advancements in the software include a 3D deformable atlas to allow for precise definition of anatomical structures and improved, streamlined workflow when using the Medtronic StealthStation platform, the company said.

“It is a vital goal to obtain the best clinical outcomes for our patients. Software – such as SureTune3 – can accurately visualize patient-specific stimulation settings and expedite the data while treating patients with DBS. Further, this software can allow our hospital server to integrate all the procedure and patient data so I can provide more personalized case management with faster programming,” Dr. Christopher Honey of the University of British Columbia said in a prepared statement.

“As the pioneer in DBS therapy with more than 30 years of experience, Medtronic is committed to continuing to advance our technology. The latest innovations to our SureTune technology allow for more precise, efficient treatment while also improving patient management with centralized data storage for easy reference. With more than 150,000 patients implanted worldwide, we strive to continue to improve both the physician and patient experience with our solutions,” Medtronic brain therapy division prez Brett Wall said in a press release.

Last September, Medtronic said the FDA granted 510(k) clearance for its StealthStation software, which is designed to help plan the placement of the leads used for deep-brain stimulation therapy.

Filed Under: Neurological, Regulatory/Compliance, Software / IT Tagged With: Medtronic

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy